Company intelligence / Profile preview
Ningbo Combireg Pharmaceutical Technology
Ningbo, Zhejiang Sheng, Chinacombireg.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ningbo Combireg Pharmaceutical Technology has completed a Phase 1 study for Salutaxel (xinlitaxel), targeting tubulin in advanced solid tumors. Early phase data focus on safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy in neoplastic indications. Another small molecule program remains in preclinical discovery stage.[1]
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Shenzhen Salubris PharmaceuticalsVersitech Ltd.
Beyond the preview
Go deeper on Ningbo Combireg Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ningbo Combireg Pharmaceutical Technology.